Article Text

Download PDFPDF
Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2

Footnotes

  • CM and BM contributed equally.

  • Handling editor Josef S Smolen

  • Contributors JS made substantial contributions to the conception of the study, and the acquisition, analysis and interpretation of data, and was involved in drafting and revising the manuscript. MBe, MBr, SC, TF, BV and CAFB were centrally involved in the acquisition and analysis of data and in revising the manuscript. RS and OD made contributions to the conception and design of the study, interpretation of data and revision of the manuscript. CM and BM made substantial contributions to conception and design of the study and were centrally involved in the acquisition, analysis and interpretation of data and in drafting and revising the manuscript. All authors have given final approval of the version to be published.

  • Funding This work was supported by the Swiss National Science Foundation (Grant: CRSII3_154490), Hartmann-Mueller Foundation.

  • Competing interests JS, MBe, MBr, SH, SC, RS, CM, CAF-B and TF have no competing interests to declare. OD had consultancy relationship and/or has received research funding from Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, EspeRare Foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Sinoxa and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis licensed. The real or perceived potential conflicts listed above are accurately stated. BM had grant/research support from AbbVie, Protagen and Novartis, and congress support from Pfizer, Roche and Actelion. In addition, BM has a patent mir-29 for the treatment of systemic sclerosis licensed. The real or perceived potential conflicts listed above are accurately stated.

  • Patient consent Obtained.

  • Ethics approval All animal experiments were approved by the cantonal authorities and performed according to the Swiss animal welfare guidelines. All studies with human biosamples were approved by the local ethics committees and the local institutional review boards.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement All data from this study were published in the article or in the online supplementary information.

View Full Text

Statistics from Altmetric.com

Footnotes

  • CM and BM contributed equally.

  • Handling editor Josef S Smolen

  • Contributors JS made substantial contributions to the conception of the study, and the acquisition, analysis and interpretation of data, and was involved in drafting and revising the manuscript. MBe, MBr, SC, TF, BV and CAFB were centrally involved in the acquisition and analysis of data and in revising the manuscript. RS and OD made contributions to the conception and design of the study, interpretation of data and revision of the manuscript. CM and BM made substantial contributions to conception and design of the study and were centrally involved in the acquisition, analysis and interpretation of data and in drafting and revising the manuscript. All authors have given final approval of the version to be published.

  • Funding This work was supported by the Swiss National Science Foundation (Grant: CRSII3_154490), Hartmann-Mueller Foundation.

  • Competing interests JS, MBe, MBr, SH, SC, RS, CM, CAF-B and TF have no competing interests to declare. OD had consultancy relationship and/or has received research funding from Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, EspeRare Foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sanofi, Sinoxa and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis licensed. The real or perceived potential conflicts listed above are accurately stated. BM had grant/research support from AbbVie, Protagen and Novartis, and congress support from Pfizer, Roche and Actelion. In addition, BM has a patent mir-29 for the treatment of systemic sclerosis licensed. The real or perceived potential conflicts listed above are accurately stated.

  • Patient consent Obtained.

  • Ethics approval All animal experiments were approved by the cantonal authorities and performed according to the Swiss animal welfare guidelines. All studies with human biosamples were approved by the local ethics committees and the local institutional review boards.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement All data from this study were published in the article or in the online supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles